Company Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications.
It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates.
The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018.
Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 286 |
| CEO | Arthur Sands |
Contact Details
Address: 1700 Owens Street, Suite 205 San Francisco, California 94158 United States | |
| Phone | 415 660 5320 |
| Website | nurixtx.com |
Stock Details
| Ticker Symbol | NRIX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | December - November |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001549595 |
| CUSIP Number | 67080M103 |
| ISIN Number | US67080M1036 |
| Employer ID | 27-0838048 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arthur T. Sands M.D., Ph.D. | Chief Executive Officer, President and Director |
| Johannes Van Houte | Chief Financial Officer |
| Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer |
| Dr. Christine Ring J.D., Ph.D. | Chief Legal Officer, Secretary and Chief Compliance Officer |
| Dr. John Kuriyan Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Arthur Weiss M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Rita Kwong | Senior Accounting Manager |
| Dr. Pasit Phiasivongsa Ph.D. | Chief Technical Officer |
| Dr. Jason Kantor Ph.D. | Chief Business Officer |
| Christopher B. Phelps Ph.D. | Senior Vice President and Head of Early Drug Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 1, 2025 | 144 | Filing |
| Jul 9, 2025 | 10-Q | Quarterly Report |
| Jul 9, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 2, 2025 | 144 | Filing |
| Apr 23, 2025 | SCHEDULE 13G/A | Filing |